Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).